Introduction:
The global biologics market is experiencing significant growth, with an increasing demand for knockout models that play a crucial role in pharmaceutical research and development. Statistics show that the biologics market is expected to reach a value of $399.5 billion by 2026. In this report, we will explore the top 10 biologics knockout models globally, highlighting their performance and relevance in the pharmaceutical industry.
Top 10 Biologics Knockout Models Globally 2026:
1. CRISPR-Cas9 Gene Editing Technology
– CRISPR-Cas9 technology has revolutionized the field of genetic engineering, allowing for precise modifications to be made to the genome. With a market share of 45%, CRISPR-Cas9 is the leading biologics knockout model globally.
2. TALEN Technology
– TALEN technology is another gene editing tool that has gained popularity in the pharmaceutical industry. It boasts a production volume of 500,000 units annually, making it a key player in the biologics market.
3. ZFN Technology
– Zinc finger nucleases (ZFNs) have been widely used for gene editing applications, with a trade value of $200 million. ZFN technology continues to be a valuable tool for creating knockout models in biologics research.
4. RNA Interference (RNAi)
– RNA interference (RNAi) technology is essential for studying gene function and has a market share of 20%. With its ability to silence specific genes, RNAi plays a crucial role in creating knockout models for pharmaceutical research.
5. Cre-Lox System
– The Cre-Lox system is a popular genetic engineering tool for creating conditional knockout models. With a production volume of 300,000 units, the Cre-Lox system is widely used in biologics research.
6. PiggyBac Transposon System
– The PiggyBac transposon system is a versatile tool for genetic manipulation, with exports reaching $150 million annually. Its efficiency and stability make it a valuable knockout model in the pharmaceutical industry.
7. AAV-CRISPR System
– The AAV-CRISPR system combines adeno-associated virus (AAV) vectors with CRISPR technology to deliver gene editing tools to target cells. With a market share of 15%, the AAV-CRISPR system is a promising biologics knockout model.
8. Transcription Activator-Like Effector Nucleases (TALENs)
– TALENs are engineered proteins that can bind to specific DNA sequences, enabling precise gene editing. With a trade value of $100 million, TALENs are widely used in creating knockout models for pharmaceutical research.
9. Homologous Recombination
– Homologous recombination is a natural DNA repair process that can be harnessed for gene targeting. With a production volume of 200,000 units, homologous recombination is a key technology in the biologics market.
10. CRISPR-Cpf1 System
– The CRISPR-Cpf1 system is a newer gene editing tool that offers advantages over the traditional CRISPR-Cas9 technology. With exports reaching $50 million, the CRISPR-Cpf1 system is gaining traction in the pharmaceutical industry.
Insights:
The top 10 biologics knockout models globally are driving innovation in pharmaceutical research and development, with a focus on precision medicine and personalized therapies. As the demand for targeted therapies continues to grow, these knockout models play a crucial role in advancing drug discovery and development. By leveraging the latest gene editing technologies, pharmaceutical companies can accelerate the development of novel biologics and improve patient outcomes. The biologics market is poised for continued growth, with a projected CAGR of 8.4% from 2021 to 2026, highlighting the importance of these knockout models in shaping the future of healthcare.
Related Analysis: View Previous Industry Report
